Cybrexa Therapeutics in BioWorld

Cybrexa Therapeutics, a New Haven, Conn.-based company developing a solid tumor-targeting technology to work with an already-approved PARP inhibitor, said it plans to submit an investigational new drug application for its lead candidate, CBX-11, by the fourth quarter of 2019. A phase I trial evaluating the drug is expected to begin in the first quarter of 2020. If preclinical findings hold, the approach could potentially enhance the therapeutic index of the PARP inhibitor, improve overall survival and limit the toxicities associated with combining PARP inhibitors and DNA-damaging chemotherapy.

View the PDF